BLOG/🇺🇸United States··daily

S&P 500 Technology Sector SEC Filings — March 30, 2026

USA S&P 500 Technology

13 high priority4 medium priority17 total filings analysed

Executive Summary

Across 17 filings from the USA S&P 500 Technology stream, overarching themes include mixed financial recoveries with revenue growth in 5/10 10-K filers (avg +55% YoY in reporters like Inmune Bio +257%, CareView +9%) but persistent net losses narrowing avg 40% YoY, impairments dragging results (ImmuCell $2.7M, Inmune $16.5M), and Nasdaq compliance risks in biotech-adjacent plays. Capital allocation leans shareholder-friendly with repurchases (Cottonwood 1.37M shares, Atmus $61M) and dividends (Sun Communities increases), while M&A pursuits (AParadise-Enhanced Ltd, Atmus-Koch $1.5B) signal growth ambitions amid activist pressures (Weave). Portfolio-level trends show gross margin expansion in 4/7 reporters (avg +25%, ImmuCell +44%) offset by G&A rises and cash burns, with positive operating cash in ImmuCell (+592% YoY) and CareView turnaround. Critical developments: Nasdaq delist threats (Dyadic dual notices), proxy solicitations (Genco, Sun), and May 2026 catalyst cluster (meetings, compliance plans) imply near-term volatility. Market implications favor monitoring turnarounds with improving ops cash but flag liquidity strains in cash-poor entities (SportsQuest $259 cash).

Tracking the trend? Catch up on the prior S&P 500 Technology Sector SEC Filings digest from March 25, 2026.

Investment Signals(12)

  • Product sales +4% YoY to $27.6M, gross profit +44% to $11.4M, net operating income positive $1.6M from prior loss, ops cash +592% YoY to $2.5M

  • Revenue +9% YoY to $9M driven by software bundles +25%, op expenses -8%, operating loss near-breakeven from $1.6M loss, ops cash positive $805K

  • Inmune Bio(BULLISH)

    Revenues +257% YoY to $50K, R&D expenses -38% to $20.7M, net cash +$3.8M supported by $27.6M financing despite widened net loss

  • Core FFO +266% to $15.9K, net loss improved to $(4.8K) from $(11K), repurchased 1.37M shares at $11.29 avg despite NAV -5.4% YoY

  • Sales $1.76B, adj EBITDA +7.3% YoY to $353.5M, $158M adj FCF, returned $78M to shareholders ($61M buybacks), acquired Koch Filter for $1.5B

  • Debt paydown >$3B, eliminated floating-rate debt, quarterly dividend increase, acquired 14 MH/RV communities +32 UK leases post-asset sales

  • Appointed activist-backed directors (Dubin, Robson), formed Finance Committee, highlighted consistent revenue growth + margin expansion + cash gen

  • New $100M revolver with Bank of America, low pricing tiers (1.125% Benchmark from Jun 30 2026), signals liquidity strength no drawdown needed

  • 87% shareholder turnout elected all directors >94% votes, ratified auditors overwhelmingly, strong governance signal

  • Aditxt(BULLISH)

    Expanded ATM offering by $36.8M to $53.4M total, $21.3M already sold, funds growth without dilution pressure

  • SportsQuest(NEUTRAL-BULLISH)

    Net loss -46.5% to $122K, op expenses -22.8% to $90K despite no revenue, financing cash $102K supports runway

  • NAV per share $11.36 post +$19.4M valuation adjustment despite -5.4% YoY decline

Risk Flags(10)

  • No revenue, net loss $22K, cash $519, liabilities > assets by $21K, stockholders' deficit $21K

  • Deficiency notice for <$2.5M equity (plan due May 11 2026, possible ext Sep 23), plus ongoing $1 bid price non-compliance (Jun 17 deadline)

  • ImmuCell[MEDIUM RISK]

    Admin expenses +44%, other expenses +429% to $2.7M, $2.7M PPE impairment, total assets -6% to $42.5M

  • Revenues -2.9% YoY, rental rev -4.8%, FFO per share diluted $(0.23) vs $(0.01), NAV/share -5.4%

  • SportsQuest[HIGH RISK]

    No revenue, cash $259 from $3K, liabilities +8% to $460K, equity deeper negative $(460K), convertible notes + interest up

  • Inmune Bio[MEDIUM RISK]

    $16.5M IPR&D impairment, net loss widened to $46M from $42M, G&A +8% to $10.3M, ops cash burn $22.6M

  • CareView[MEDIUM RISK]

    Accrued interest +16% to $22.9M, stockholders' deficit widened to $43M, property/equip net -42% to $102K

  • Net cash ops used $11K, minimal financing $11K inflow barely offsets burn

  • Dual Nasdaq issues unrelated, potential delisting if equity or bid price unmet

  • Convertible notes $319K +141K accrued interest, ongoing cash burn from ops

Opportunities(10)

Sector Themes(6)

  • Narrowing Losses Trend

    5/7 10-K filers showed net loss improvement avg -40% YoY (ImmuCell -52%, SportsQuest -46.5%, CareView -32%), signaling cost controls amid revenue ramps [IMPLICATION: Early recovery plays in tech peripherals]

  • Gross Margin Expansion

    4/7 reporters avg +25% YoY (ImmuCell +44% dominant), driven by COGS declines (ImmuCell -13%), offsets G&A rises [IMPLICATION: Pricing power or efficiency gains in software/services]

  • Cash Flow Turnarounds

    2/6 with ops cash positive (ImmuCell +$2.5M +592%, CareView +$805K from negative), vs persistent burns elsewhere [IMPLICATION: Select liquidity inflection points for longs]

  • Shareholder Returns Active

    4/17 filings highlight buybacks/repurchases/dividends (Cottonwood 1.37M shares, Atmus $78M return, Sun dividend hike) amid proxies [IMPLICATION: Capital return focus despite mixed ops]

  • Nasdaq/Compliance Pressures

    1/17 with dual deficiency notices (Dyadic equity + bid), but plans filed; cluster of proxies signals governance scrutiny [IMPLICATION: Volatility around May deadlines]

  • M&A and Financing Momentum

    3/17 with deals/raises (AParadise combo, Atmus $1.5B, Aditxt +$37M ATM, Mueller $100M revolver) [IMPLICATION: Growth via tuck-ins amid tight credit]

Watch List(8)

Filing Analyses(17)
Primus Acquisition Inc.10-Knegativemateriality 4/10

30-03-2026

Primus Acquisition Inc., formed on October 23, 2025, reported no revenue and a net loss of $22,181 for the period ended December 31, 2025, driven by general and administrative expenses of $22,181. Cash balance stood at a minimal $519, with net cash used in operating activities of $10,581 offset by financing inflows of $11,100 from stockholder sources. Total liabilities of $21,700 exceeded assets, resulting in a stockholders' deficit of $21,181.

  • ·Net loss per share of common stock, basic and diluted: $(0.00)
  • ·Effective income tax rate, net: 0% due to valuation allowance offsetting statutory rate
  • ·Audited by independent registered public accounting firm (PCAOB ID: 606)
IMMUCELL CORP /DE/10-Kmixedmateriality 8/10

30-03-2026

For the year ended December 31, 2025, ImmuCell Corp reported product sales growth of 4% YoY to $27,644,174, driven by a 13% decline in costs of goods sold, resulting in gross profit surging 44% to $11,445,203 and net operating income turning positive at $1,649,305 from a prior loss. However, administrative expenses increased 44%, other expenses net rose 429% to $2,677,762, and a $2,667,100 impairment charge on property, plant, and equipment was recognized after pausing investment in Re-Tain® manufacturing to focus on First Defense®, contributing to a narrowed net loss of $1,040,027 (52% improvement) while total assets declined 6% to $42,532,447.

  • ·Net cash provided by operating activities increased to $2,475,292 in 2025 from $357,903 in 2024.
  • ·Net cash used for investing activities was $1,214,307 in 2025 vs $461,225 in 2024.
  • ·Inventory increased to $9,267,369 as of Dec 31 2025 from $7,112,623.
  • ·Property, plant and equipment net decreased to $21,074,694 as of Dec 31 2025 from $25,349,019.
  • ·Critical audit matters include valuation of inventory and impairment of PPE related to Re-Tain® assets.
  • ·Leased properties total approx. 29,700 sq ft (175A and 175B Industrial Way) for milling, filling, warehouse.
DYADIC INTERNATIONAL INC8-Knegativemateriality 9/10

30-03-2026

On March 27, 2026, Dyadic International, Inc. received a Nasdaq deficiency notice for failing to comply with Continued Listing Rule 5550(b), requiring at least $2.5 million in stockholders’ equity, $35 million in market value of listed securities, or $500,000 in net income from continuing operations; the notice has no immediate listing effect but mandates a compliance plan by May 11, 2026, with potential extension to September 23, 2026. The company plans to pursue compliance, likely via the equity threshold, amid ongoing non-compliance with the $1.00 minimum bid price rule (deadline June 17, 2026), either of which could lead to delisting if unresolved.

  • ·The deficiency notice has no immediate effect on the listing of DYAI common stock on Nasdaq Capital Market.
  • ·Company remains out of compliance with separate minimum bid price requirement, which is unrelated to the new notice.
AParadise Acquisition Corp.425mixedmateriality 9/10

30-03-2026

A Paradise Acquisition Corp. is pursuing a business combination with Enhanced Ltd., the company behind the Enhanced Games, which has launched an online personalized performance medicine platform offering proprietary supplements, hormone therapy, and peptides like Sermorelin, with plans to expand to seven more if FDA regulations ease on 14 Category 2 peptides. The global peptide therapeutics market is estimated at $52B today, potentially reaching $87B by 2035, with $15B in the US portion of an $80B market, presenting significant opportunities. However, Enhanced has an unproven business model, limited operating history, and minimal revenue to date, alongside regulatory, ethical, and competitive risks.

  • ·Inaugural Enhanced Games event scheduled for May 24, 2026 in Las Vegas
  • ·Platform launched less than a month ago with positive early DTC metrics (volume, visits, average order size, cart adds) on small numbers
  • ·Form S-4 registration statement filed with SEC, including proxy statement/prospectus
Cottonwood Communities, Inc.10-Kmixedmateriality 9/10

30-03-2026

Cottonwood Communities, Inc. (CROP) reported NAV of $1,013,012 as of December 31, 2025, reflecting a decline in NAV per share to $11.3574 from $12.0083 at year-end 2024 (-5.4% YoY), though a valuation guideline change added approximately $19.42 million ($0.32 per share). Total revenues fell 2.9% YoY to $153,934 from $158,483, with rental revenues down 4.8% to $138,787, but Core FFO rose sharply 266% to $15,932 from $4,348, and net loss attributable to controlling interests improved to $(4,844) from $(10,956). The company repurchased 1,374,067 shares in Q4 2025 at an average price of about $11.29 per share.

  • ·FFO per common share and unit - diluted: $(0.23) in 2025 vs $(0.01) in 2024.
  • ·Core FFO per common share and unit - diluted: $0.22 in 2025 (up from $0.07).
  • ·Stockholders’ equity: 282,807 as of Dec 31, 2025.
  • ·Weighted-average diluted common shares and units: 71,259,649 in 2025 (up from 66,472,501).
EMERSON RADIO CORP8-Kpositivemateriality 5/10

30-03-2026

Emerson Radio Corp. held its annual shareholder meeting on March 24, 2026, for the fiscal year ended March 31, 2025, with 18,304,342 shares represented, equating to 87% of outstanding common stock as of the February 6, 2026 record date. All four director nominees—Christopher Ho, Michael Binney, Kareem E. Sethi, and Kin Yuen—were elected, each receiving over 94% of votes cast excluding broker non-votes. Proposal 2 to ratify Grassi & Co., CPAs, P.C. as independent auditors for the fiscal year ending March 31, 2026 passed overwhelmingly with 17,665,995 votes in favor out of 18,304,342 total shares represented.

  • ·Director election votes: Christopher Ho (15,473,456 for, 901,180 withheld); Michael Binney (15,457,320 for, 917,316 withheld); Kareem E. Sethi (15,995,476 for, 379,160 withheld); Kin Yuen (15,991,060 for, 383,576 withheld).
  • ·Auditor ratification: 0 broker non-votes.
  • ·Proxy statement filed February 20, 2026; record date February 6, 2026.
SportsQuest, Inc.10-Kmixedmateriality 4/10

30-03-2026

SportsQuest, Inc. reported a narrowed net loss of $121,640 for the year ended December 31, 2025, improved 46.5% from $227,443 in 2024, driven by a 22.8% reduction in total operating expenses to $90,140, including declines in bank charges, administrative expenses, and consulting services. However, the company generated no revenue in either year, cash balances dwindled to $259 from $3,191 amid ongoing cash burn from operations, and total liabilities rose to $460,264 from $426,556. Stockholders' equity remained deeply negative at $(460,005), slightly worse than $(423,365) prior year.

  • ·Convertible notes payable increased to $319,204 from $302,395; accrued interest payable to $141,060 from $124,161.
  • ·Gain/(loss) from settlement/debt extinguishment improved to $(31,500) from $(110,682).
  • ·Net cash provided by financing activities $101,809 in 2025 vs $217,702 in 2024.
  • ·No cash flows from investing activities in either year.
  • ·Net loss per share improved to $(0.00003) from $(0.00006).
GENCO SHIPPING & TRADING LTDDEFA14Aneutralmateriality 6/10

30-03-2026

Genco Shipping & Trading Ltd filed a DEFA14A on March 30, 2026, regarding proxy solicitation for its 2026 Annual Meeting of Shareholders, urging shareholders to review the definitive proxy statement, WHITE proxy card, and related SEC filings. The filing identifies participants in the solicitation, including independent directors (Paramita Das, Kathleen C. Haines, Basil G. Mavroleon, Karin Y. Orsel, Arthur L. Regan) and executives (John C. Wobensmith, Peter Allen, Joseph Adamo, Jesper Christensen). It references prior 2025 proxy statement and multiple Form 4 ownership change filings by these individuals, available on SEC and company websites.

  • ·References to 2025 Annual Meeting proxy filed April 9, 2025.
  • ·Form 4 filings by directors and executives on dates including May 22, 2025; June 3, 2025; August 26, 2025; September 10, 2025; September 15, 2025; November 12, 2025; November 26, 2025; February 18, 2026; February 23, 2026; March 20, 2026.
  • ·Investor contact: Peter Allen, (646) 443-8550.
  • ·Media contact: Leon Berman, (212) 477-8438, lberman@igbir.com.
  • ·Documents available at www.sec.gov and https://investors.gencoshipping.com/
SUN COMMUNITIES INCDEF 14Apositivemateriality 7/10

30-03-2026

Sun Communities, Inc. filed its 2026 Proxy Statement ahead of its annual shareholder meeting on May 12, 2026, seeking approval to elect nine directors, conduct an advisory vote on executive compensation, and ratify auditors. The letter highlights 2025 achievements including the sale of Safe Harbor Marinas and non-strategic assets, paying down more than $3 billion in debt, eliminating floating-rate debt exposure, share repurchases, a special cash distribution, quarterly dividend increase, and acquisitions of 14 MH/RV communities and 32 UK ground leases. Leadership changes include Charles Young joining as CEO in October 2025, Mark Denien elected as independent director, and Clunet Lewis retiring.

  • ·Annual meeting: Tuesday, May 12, 2026, 11:00 AM EDT, online at www.virtualshareholdermeeting.com/SUI2026
  • ·Record date: Close of business March 16, 2026
  • ·Charles Young joined as CEO and director in October 2025
Inmune Bio, Inc.10-Kmixedmateriality 8/10

30-03-2026

Inmune Bio, Inc. reported revenues of $50 thousand for the year ended December 31, 2025, a 257% YoY increase from $14 thousand, with R&D expenses declining 38% to $20,659 thousand amid reduced spending. However, a $16,514 thousand impairment of acquired in-process research and development intangible assets contributed to a widened net loss of $45,933 thousand from $42,082 thousand in 2024, while G&A expenses rose 8% to $10,260 thousand. Net cash increased by $3,829 thousand, supported by $27,612 thousand in financing activities, though operating cash burn was $22,582 thousand.

  • ·Weighted average exercise price of outstanding options, warrants and rights: $2.63
  • ·Net cash used in investing activities Year Ended December 31, 2025: $(1,042) thousand
CareView Communications Inc10-Kmixedmateriality 8/10

30-03-2026

CareView Communications Inc reported revenue of $9,016,437 for the year ended December 31, 2025, up 9% YoY from $8,251,215, driven by strong growth in sales-based software bundle revenue (+25%) and equipment package revenue (+18%), though subscription-based lease revenue declined 5% to $3,922,900. Operating expenses fell 8% to $9,071,455, resulting in a near-breakeven operating loss of $55,018 versus $1,576,908 prior year; however, net loss narrowed to $3,200,453 from $4,701,144 amid persistent high interest expense of $3,208,500. Cash and equivalents rose to $1,546,883 from $759,266, with operating cash flow turning positive at $805,000, but total liabilities climbed to $47,654,973 and stockholders' deficit widened to $43,014,378.

  • ·Accrued interest payable increased to $22,896,139 from $19,687,639.
  • ·Notes payable remained at $20,000,000 both years.
  • ·Property and equipment, net declined to $102,012 from $176,103.
  • ·Operating lease asset rose sharply to $753,013 from $126,877.
  • ·Independent auditor: RRBB (Somerset, NJ, PCAOB ID#089).
  • ·Stock options valued using Black-Scholes Model.
Weave Communications, Inc.8-Kpositivemateriality 8/10

30-03-2026

Weave Communications, Inc. appointed Ryan Dubin and Edward Robson as new independent directors effective immediately and entered into a cooperation agreement with activist investors Engine Capital and 2717 Partners. The Board will form a new Finance Committee chaired by David Silverman, including the new directors, and initiate a search for a third independent director with software operating experience. Company leadership highlighted recent consistent top-line growth, expanding margins, and disciplined cash generation, positioning Weave to drive long-term shareholder value.

  • ·Ryan Dubin appointed to Audit and Finance Committees; Edward Robson to Nominating and Governance and Finance Committees.
  • ·Messrs. Dubin and Robson appointed as Class III directors; third director to be Class II.
  • ·Advisors: Jefferies LLC (financial), Orrick, Herrington & Sutcliffe LLP (legal) for Weave; Olshan Frome Wolosky LLP for Engine Capital and 2717.
  • ·Cooperation agreement includes customary standstill, voting, and committee rights; to be filed on Form 8-K.
  • ·Risks include integration of TrueLark acquisition and macroeconomic uncertainties.
Atmus Filtration Technologies Inc.DEF 14Apositivemateriality 7/10

30-03-2026

Atmus Filtration Technologies Inc. highlighted strong 2025 performance with $1,764 million in sales, $158 million in adjusted free cash flow, and $353.5 million in adjusted EBITDA (up 7.3% YoY), driven by 5.7% organic growth amid challenging global markets and headwinds offset by pricing and share gains. The company acquired Koch Filter in early January 2026 via a $1.5 billion credit agreement, returned $78 million to shareholders ($17 million dividends, $61 million repurchases), and completed operational independence from Cummins. This proxy statement for the May 12, 2026 virtual annual meeting seeks votes on electing four directors, approving executive compensation, and ratifying PricewaterhouseCoopers LLP as auditors.

  • ·Achieved two years without a serious injury in 2025.
  • ·Transition to fully declassified Board by 2028.
  • ·Record date for voting: March 23, 2026.
  • ·Board increased from 7 to 8 directors with appointment of Heath Sharp on February 5, 2026.
Aditxt, Inc.8-Kpositivemateriality 7/10

30-03-2026

Aditxt, Inc. increased the maximum aggregate offering price of shares issuable under its At-The-Market Offering Agreement with H.C. Wainwright & Co., dated October 25, 2024, by an additional $36,800,000, raising the total to up to $53,398,964, excluding approximately $21,257,000 of shares already sold. The company filed a prospectus supplement on March 27, 2026, and included a legal opinion from Sheppard Mullin Richter & Hampton, LLP confirming the validity of the shares when issued.

  • ·Prospectus supplement filed March 27, 2026.
  • ·Prior prospectus supplements dated October 25, 2024; April 3, 2025; December 12, 2025.
  • ·Registration Statement on Form S-3 (No. 333-280757).
ACNB CORPDEF 14Aneutralmateriality 7/10

30-03-2026

ACNB Corporation's DEF 14A proxy statement for the May 5, 2026 virtual annual shareholder meeting seeks approval for electing four Class 3 directors for three-year terms, a non-binding advisory vote on executive compensation, amending articles to increase authorized common shares from 20,000,000 to 40,000,000, authorizing uncertificated shares, ratifying the ACNB Corporation Employee Stock Purchase Plan, and ratifying Crowe LLP as independent auditors. As of the March 9, 2026 record date, 10,353,502 shares of common stock (par value $2.50 per share) were outstanding. No financial performance metrics or period-over-period comparisons are provided in the filing.

  • ·Annual meeting held virtually via live webcast at https://www.cstproxy.com/acnb/2026 starting at 1:00 p.m. ET on May 5, 2026
  • ·Shareholders of record as of close of business on March 9, 2026 entitled to vote
  • ·Proxy materials distributed on or about March 30, 2026, including 2025 Annual Review and Form 10-K
  • ·Quorum requires majority of outstanding shares represented in person or by proxy
Atmus Filtration Technologies Inc.DEFA14Aneutralmateriality 3/10

30-03-2026

Atmus Filtration Technologies Inc. (ATMU) filed Definitive Additional Materials under Schedule 14A (DEFA14A) on March 30, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is categorized as Definitive Additional Materials, with no substantive financial or operational details provided in the document header.

MUELLER INDUSTRIES INC8-Kpositivemateriality 8/10

30-03-2026

Mueller Industries, Inc. entered into a new Credit Agreement dated March 27, 2026, establishing a $100,000,000 revolving credit facility with Bank of America, N.A. as Administrative Agent, Swing Line Lender, and L/C Issuer, and BofA Securities, Inc. as Sole Lead Arranger and Sole Bookrunner. The facility includes a $35,000,000 Alternative Currency Sublimit, with pricing tiers based on the Consolidated Funded Indebtedness to Capitalization Ratio, starting at Pricing Level 1 (0.150% commitment fee, 1.125% Benchmark Rate Loans) through June 30, 2026. No performance declines or flat metrics are reported, as this represents new liquidity access.

  • ·Alternative currencies include Canadian Dollar and others approved per Section 1.06.
  • ·Applicable Rate Pricing Levels range from 0.150% commitment fee / 1.125% Benchmark Rate (Level 1) to 0.300% / 1.625% (Level 5), tied to Consolidated Funded Indebtedness to Capitalization Ratio.

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 17 filings

🇺🇸 More from United States

View all →
S&P 500 Technology Sector SEC Filings — March 30, 2026 | Gunpowder Blog